The facility is located in a notified industrial area called Raichur Industrial Growth Centre on the outskirts of Raichur, Karnataka, India (about 16 km away from the Raichur city). It is near (2 km) to Karnataka State Highway No. 167 connecting Raichur and Hyderabad. The facility is about 180 km distance from Hyderabad Rajiv Gandhi International Airport.
Raichem was established in 2009 as a joint venture and the construction of the plant was completed in 2015. In this period the company manufactured intermediates for the production of ursodeoxcholic acid (UDCA) API. In 2018 the company was fully acquired by ICE Pharma and shortly afterwards it started manufacturing UDCA API to supply the Indian market and South East Asia.
Research & Development Activities
Raichem R&D has well equipped labs and qualified scientists that support the development of generic APIs and process improvement of existing products. We have deep knowledge of the complex chemistry to synthesise, isolate and purify different bile acid derivatives. Our team thrives on the challenges of developing new or improved processes and scaling them up from the laboraotory to industrial manufacture.
The plant is well equipped with both glass-lined multi-purpose reaction vessels and agitated nutsche filter dryers and is focused on the manufacturing of UDCA advanced intermediates and final API.
Since its foundation the facility has been inspected and certified by a number of Health Authorities. Raichem has obtained ISO 5001, ISO 9001, ISO 14001 and ISO 45001 certification.
The plant has been audited and obtained the following ISO certification:
Corporate Social Responsibility Policy
Raichem is committed to the health and safety of their employees, sub-contractors, visitors, care of the environment and prevention of accidents, health hazards and Air & Water pollution.
Environment, Health & Safety Policy
Raichem Medicare Private Limited, in India is committed to undertake CSR activities in accordance with the provisions of Section 135 of the Indian Companies Act, 2013 and relatedRules. Raichem Medicare Private Limited commits itself to contribute to the society in ways possible for the organization and will set up its committed core CSR Committee (When applicable), as a means for fulfilling this commitment.
Ursodeoxycholic acid is an API used for the treatment of primary biliary cirrhosis (PBC), dissolution of radiolucent gallstones in patients with a functioning gallbladder, and treatment of hepatobiliary disorders associated with cystic fibrosis in pediatric patients.
Kumar Gourave Singh
Head API Sales and Marketing, India, SEA and Middle East
Pramod joined Raichem Medicare pvt Ltd as Managing Director since 1st of April 2016, and was instrumental in setting up the manufacturing plant and building Raichem team Pramod is a Company Director, reporting to the Group CEO Agostino Barazza, and is responsible for the general administration of the plant. Pramod has 33 years of experience in the pharmaceutical industry, having worked with major pharmaceutical companies. Pramod holds a masters in Pharmaceutical science and Ph.D in Pharmaceutical chemistry.
Mr Singh graduated in Pharmacy from Manipal Academy of higher education in India. He has 17 years of experience in most facets of API & intermediates sales and marketing. He previously worked for companies including Mylan, Neuland, GVK and Orchid Chem.
24, 25, 26 & 26P, Raichur Industrial Growth Centre, Raichur Rd, Chicksugur, Karnataka 584134, India
Main line+91 95133 00524
Get in touch with Raichem today